| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Endocrinology, Vol 116, 6-10, Copyright © 1985 by Endocrine Society
ARTICLES |
CE Gomez-Sanchez, EP Gomez-Sanchez, JS Smith, MW Ferris and MF Foecking
It has been recently demonstrated that cortisol can be metabolized, producing 18-hydroxycortisol and 18-oxocortisol, following the same pathway by which corticosterone is transformed into 18- hydroxycorticosterone and aldosterone. The influence of a hydroxy group in the 17 alpha position of aldosterone or an aldehyde (actually 11-18 hemiacetal) in the 13-methyl of cortisol on the mineralocorticoid and glucocorticoid activities were studied and compared with the parent steroids. The ability of 18-oxocortisol to complete with [3H]aldosterone for binding to the cytosol receptor of rat renal slices was 8.1% in comparison to unlabeled aldosterone. The addition of a specific glucocorticoid 11 beta, 17 beta-dihydroxy-17 alpha-pregnane- 1,4,6- trien-20-yn-21-methyl-3-one decreased this binding to 5.6%. The ability of 18-oxocortisol to compete with [3H]dexamethasone for binding to the renal cytosol receptor was 0.2% that of unlabeled dexamethasone and in the HTC whole cell assay was 1.06% and 3.8% that of unlabeled dexamethasone and cortisol, respectively. The mineralocorticoid activity of 18-oxocortisol in the adrenalectomized rat bioassay was 0.6% that of aldosterone. The glucocorticoid activity in in vitro bioassays was 3.1% compared with that of a cortisol when the induction of tyrosine aminotransferase in HTC cells was measured and 4% when the inhibition of fibroblast L-929 growth was measured. The significance of 18-oxocortisol in the pathogenesis of the hypertension in patients with primary aldosteronism is still unclear.
This article has been cited by other articles:
![]() |
L. Mosso, C. E. Gomez-Sanchez, M. F. Foecking, and C. Fardella Serum 18-Hydroxycortisol in Primary Aldosteronism, Hypertension, and Normotensives Hypertension, September 1, 2001; 38(3): 688 - 691. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Stowasser, A. W. Bachmann, P. R. Huggard, T. R. Rossetti, and R. D. Gordon Severity of Hypertension in Familial Hyperaldosteronism Type I: Relationship to Gender and Degree of Biochemical Disturbance J. Clin. Endocrinol. Metab., June 1, 2000; 85(6): 2160 - 2166. [Abstract] [Full Text] |
||||
![]() |
M. Stowasser, P. R. Huggard, T. R. Rossetti, A. W. Bachmann, and R. D. Gordon Biochemical Evidence of Aldosterone Overproduction and Abnormal Regulation in Normotensive Individuals with Familial Hyperaldosteronism Type I J. Clin. Endocrinol. Metab., November 1, 1999; 84(11): 4031 - 4036. [Abstract] [Full Text] |
||||
![]() |
W. R. Litchfield, C. Coolidge, P. Silva, R. P. Lifton, F. Fallo, G. H. Williams, and R. G. Dluhy Impaired Potassium-Stimulated Aldosterone Production: A Possible Explanation for Normokalemic Glucocorticoid-Remediable Aldosteronism J. Clin. Endocrinol. Metab., May 1, 1997; 82(5): 1507 - 1510. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |